Peter Van Veldhuizen, M.D.

Dr. Van Veldhuizen completed his residency training followed by a Hematology/ Oncology fellowship at the University of Kansas Medical Center. He is board-certified in Internal Medicine, Hematology, and Oncology. After spending much of his career in Kansas City where his primary clinical focus was the treatment of Genitourinary Malignancies (GU), in 2020 he joined the University of Rochester and the Wilmot Cancer Center to lead their GU Medical Oncology Program.

Dr. Van Veldhuizen sees patients with kidney, bladder, testicular, and prostate cancer. He is involved in helping formulate multidisciplinary treatment plans, administering chemotherapy, and managing symptoms related to both the cancer and its treatment. He also has a clinical focus on cancer survivorship and addressing all aspects related to the cancer diagnosis.

Professional Background

Dr. Van Veldhuizen is a Professor of Internal Medicine at the University of Rochester Medical Center and currently leads the GU Medical Oncology Program. He also serves as the chair of the Genitourinary Working Group which provides oversight and direction for the GU Clinical Trial Research Program. He also currently serves on the American Society of Clinical Oncology's (ASCO) Clinical Guidelines Committee which provides treatment guidelines for practicing Oncologists. He has served as a grant reviewer for the Department of Defense Prostate Cancer Research Program and is currently a committee member for an ASCO expert panel focusing on developing treatment guidelines for advanced kidney cancer.
Before coming to Rochester, he served as chair of the Kansas City Veteran Affairs Hematology/Oncology Program and then served as the Division Director of Hematology/ Oncology at the University of Kansas Medical Center. He is an advocate for addressing all aspects of the cancer diagnosis.

Research